The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Anti-TNF Agents May Improve Clinical Symptoms of Ankylosing Spondylitis

Anti-TNF Agents May Improve Clinical Symptoms of Ankylosing Spondylitis

May 21, 2015 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Ankylosing spondylitis primarily affects the joints and ligaments of the spine, but may also have an impact on other joints. Patients experience pain and stiffness that limit mobility in the back and other affected joints. Symptoms can come and go, last for long periods of time and be severe. Anti-tumor necrosis factor (anti-TNF) drugs are prescribed to patients to reduce inflammation in the joints with the hope that they will also prevent joint damage. Although anti-TNF drugs improve symptoms of inflammation, they make patients more vulnerable to infection, leading physicians to wonder if the benefits offset the risks.

You Might Also Like
  • Anti-TNF-Alpha Agents May Improve Endothelial Function Patients with RA
  • Clinical Trials Confirm Secukinumab Can Effectively Treat Ankylosing Spondylitis
  • Do Patients with Ankylosing Spondylitis in Remission Still Need TNF Inhibitors?
Explore This Issue
June 2015
Also By This Author
  • Fellowship Recruitment Goes Virtual in 2020: A Conversation with 3 Fellowship Program Directors

In a recent Cochrane review, researcher Lara J. Maxwell, managing editor, Cochrane Musculoskeletal Group at the Ottawa Hospital Research Institute in Canada, and colleagues, report moderate- to high-quality evidence that anti-TNF agents are effective at improving clinical symptoms in patients with ankylosing spondylitis.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The team analyzed results from randomized controlled trials on the effects of four anti-TNF drugs on ankylosing spondylitis—adalimumab, etanercept, golimumab and infliximab—and concluded there is no evidence of an increase in serious adverse events in patients receiving anti-TNF.

The team identified 21 trials with 3,308 participants published through June 2014. Most of the studies were funded by pharmaceutical companies. The package inserts for anti-TNF agents describe the possible side effects of serious infections, such as tuberculosis or upper respiratory tract infection. Certain types of cancer are also listed as a potential rare complication. The Cochrane review did not find any of these serious adverse events in any of the studies. The authors noted, however, that anti-TNF trials were of short duration (< 24 weeks), and thus enabled them only to draw conclusions about the short-term toxicity profile of anti-TNF. Based on their systemic literature review, they determined that short-term toxicity profile to be acceptable.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Treatment with anti-TNF drugs was associated with improved pain function and slight improvement in spinal inflammation as measured by magnetic resonance imaging. The authors calculated the 40% response according to the improvement criteria of the Assessment of SpondyloArthritis international Society (ASAS40) for each of the different anti-TNF drugs. On average, 13% of patients in the placebo group experienced improvement. By comparison, 46% of patients receiving adalimumab, 43% of patients receiving etanercept, 38% of patients receiving golimimab and 53% of patients receiving infliximab met ASAS40 treatment goals.

Patients receiving anti-TNF treatment also were more likely to achieve partial remission of symptoms when compared with placebo. Partial remission was defined as a value of < 2 on a 0–10 scale of pain, function or inflammation. Placement on the scale was determined by morning stiffness and patient overall well-being. The review found that, although only 3% of patients in the placebo group experienced partial remission, many patients in the treatment groups achieved remission: 19% who received adalimumab, 13% who received etanercept, 16% who received golimumab and 47% who received infliximab.

Pages: 1 2 | Single Page

Filed Under: Conditions, Drug Updates, Spondyloarthritis, Systemic Inflammatory Syndromes Tagged With: Ankylosing Spondylitis, anti-tumor necrosis factor, Drugs, inflammation, patient care, Research, therapyIssue: June 2015

You Might Also Like:
  • Anti-TNF-Alpha Agents May Improve Endothelial Function Patients with RA
  • Clinical Trials Confirm Secukinumab Can Effectively Treat Ankylosing Spondylitis
  • Do Patients with Ankylosing Spondylitis in Remission Still Need TNF Inhibitors?
  • Neutralizing IL-23 and Its Targets May Improve Ankylosing Spondylitis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)